Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 17/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.67 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.67 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.67 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.62 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Genaconazole SCHEMBL9774648 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Genaconazole SCHEMBL30011920 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Genaconazole SCHEMBL8937940 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Genaconazole SCHEMBL8937907 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL31512306 | 0.91 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL9119825 | 0.90 | CYP3A4 (0.66) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL9044739 | 0.89 | CYP3A4 (0.64) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL9044551 | 0.89 | CYP3A4 (0.64) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL9044565 | 0.89 | CYP3A4 (0.64) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL9118073 | 0.89 | CYP3A4 (0.63) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-01-17 | — | — | US | claimed |
| EP-1757609-A1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-02-28 | — | — | EP | claimed |
| US-20050038038-A1 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2005-02-17 | — | — | US | claimed |
| EP-0829478-A2 | N-Benzylimidazolium and N-benzyltriazolium derivatives, their preparation and their use as antifungal and antimycotic agents | F. HOFFMANN-LA ROCHE AG (CH) | 1998-03-18 | — | — | EP | claimed |
| US-4988722-A | Fungicide solutions for injections | SCHERING CORPORATION (US) | 1991-01-29 | — | — | US | claimed |
| JP-3101666-A | — | — | None | — | — | JP | disclosed |
| EP-1757609-B1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-7910593-B2 | Water-soluble prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7459561-B2 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2008-12-02 | — | — | US | disclosed |
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-01-17 | — | — | US | disclosed |
| US-7189858-B2 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2007-03-13 | — | — | US | disclosed |
| EP-1757609-A1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-0829478-A2 | N-Benzylimidazolium and N-benzyltriazolium derivatives, their preparation and their use as antifungal and antimycotic agents | F. HOFFMANN-LA ROCHE AG (CH) | 1998-03-18 | — | — | EP | disclosed |
| WO-1997031903-A1 | AZOLE COMPOUNDS ENDOWED WITH ANTIMYCOTIC ACTIVITY FOR HUMAN AND VETERINARY USE | ZAMBON GROUP S.P.A. (IT) | 1997-09-04 | — | — | WO | disclosed |
| US-5159089-A | Using a sulfur methylide compound | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-10-27 | — | — | US | disclosed |
| JP-H03101666-A | METHOD FOR OBTAINING OPTICALLY ACTIVE SULFONE DERIVATIVE | SUMITOMO PHARMACEUT CO LTD | 1991-04-26 | — | — | JP | disclosed |
| EP-0415320-A2 | Selective production of threo-epoxy compounds | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1991-03-06 | — | — | EP | disclosed |
| US-4988722-A | Fungicide solutions for injections | SCHERING CORPORATION (US) | 1991-01-29 | — | — | US | disclosed |
| EP-0405502-A2 | Optical resolution of sulfone derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1991-01-02 | — | — | EP | disclosed |
| EP-0322800-A1 | Process for preparation of sulfone derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1989-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038038-A1 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, NAALAD2 | CYP3A4 379/4885CYP2C9 1754/4885CYP2C19 1828/4885 |
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | ADH1A, ADH1C, SLC43A1 | CYP3A4 123/4885CYP2C9 135/4885CYP2C19 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.